Literature DB >> 36036929

Analysis of Neutralizing Antibody Levels in Children and Adolescents Up to 16 Months After SARS-CoV-2 Infection.

Chee Fu Yung1, Seyed Ehsan Saffari2, Shirley Yun Yan Mah3, Natalie Woon Hui Tan1, Wan-Ni Chia3, Koh Cheng Thoon1, Lin-Fa Wang3.   

Abstract

Entities:  

Year:  2022        PMID: 36036929      PMCID: PMC9425283          DOI: 10.1001/jamapediatrics.2022.3072

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   26.796


× No keyword cloud information.
  6 in total

1.  Comparative Analysis of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children.

Authors:  Jiahui Li; Koh Cheng Thoon; Chia Yin Chong; Matthias Maiwald; Kai Qian Kam; Karen Nadua; Natalie Wh Tan; Chee Fu Yung
Journal:  Ann Acad Med Singap       Date:  2020-08       Impact factor: 2.473

2.  A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.

Authors:  Chee Wah Tan; Wan Ni Chia; Xijian Qin; Pei Liu; Mark I-C Chen; Charles Tiu; Zhiliang Hu; Vivian Chih-Wei Chen; Barnaby E Young; Wan Rong Sia; Yee-Joo Tan; Randy Foo; Yongxiang Yi; David C Lye; Danielle E Anderson; Lin-Fa Wang
Journal:  Nat Biotechnol       Date:  2020-07-23       Impact factor: 54.908

3.  Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England.

Authors:  Anna A Mensah; Helen Campbell; Julia Stowe; Giulia Seghezzo; Ruth Simmons; Joanne Lacy; Antoaneta Bukasa; Shennae O'Boyle; Mary E Ramsay; Kevin Brown; Shamez N Ladhani
Journal:  Lancet Child Adolesc Health       Date:  2022-03-28

4.  Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis.

Authors:  Russell M Viner; Oliver T Mytton; Chris Bonell; G J Melendez-Torres; Joseph Ward; Lee Hudson; Claire Waddington; James Thomas; Simon Russell; Fiona van der Klis; Archana Koirala; Shamez Ladhani; Jasmina Panovska-Griffiths; Nicholas G Davies; Robert Booy; Rosalind M Eggo
Journal:  JAMA Pediatr       Date:  2021-02-01       Impact factor: 16.193

5.  Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection.

Authors:  Megan S Butler; Elizabeth Jinks; Gokhan Tut; Paul Moss; Shamez Ladhani; Alexander C Dowell; Tara Lancaster; Panagiota Sylla; Jusnara Begum; Rachel Bruton; Hayden Pearce; Kriti Verma; Nicola Logan; Grace Tyson; Eliska Spalkova; Sandra Margielewska-Davies; Graham S Taylor; Eleni Syrimi; Frances Baawuah; Joanne Beckmann; Ifeanyichukwu O Okike; Shazaad Ahmad; Joanna Garstang; Andrew J Brent; Bernadette Brent; Georgina Ireland; Felicity Aiano; Zahin Amin-Chowdhury; Samuel Jones; Ray Borrow; Ezra Linley; John Wright; Rafaq Azad; Dagmar Waiblinger; Chris Davis; Emma C Thomson; Massimo Palmarini; Brian J Willett; Wendy S Barclay; John Poh; Gayatri Amirthalingam; Kevin E Brown; Mary E Ramsay; Jianmin Zuo
Journal:  Nat Immunol       Date:  2021-12-22       Impact factor: 31.250

6.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.

Authors:  Sheila F Lumley; Denise O'Donnell; Nicole E Stoesser; Philippa C Matthews; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Fiona Warren; Liam J Peck; Thomas G Ritter; Zoe de Toledo; Laura Warren; David Axten; Richard J Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Meera Chand; Derrick W Crook; Anne-Marie O'Donnell; Christopher P Conlon; Koen B Pouwels; A Sarah Walker; Tim E A Peto; Susan Hopkins; Timothy M Walker; Katie Jeffery; David W Eyre
Journal:  N Engl J Med       Date:  2020-12-23       Impact factor: 91.245

  6 in total
  1 in total

1.  Risk for severe outcomes of COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany.

Authors:  Anna-Lisa Sorg; Markus Hufnagel; Maren Doenhardt; Natalie Diffloth; Horst Schroten; Rüdiger von Kries; Reinhard Berner; Jakob Armann
Journal:  Eur J Pediatr       Date:  2022-08-13       Impact factor: 3.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.